JP2021518374A5 - - Google Patents
Info
- Publication number
- JP2021518374A5 JP2021518374A5 JP2020550082A JP2020550082A JP2021518374A5 JP 2021518374 A5 JP2021518374 A5 JP 2021518374A5 JP 2020550082 A JP2020550082 A JP 2020550082A JP 2020550082 A JP2020550082 A JP 2020550082A JP 2021518374 A5 JP2021518374 A5 JP 2021518374A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- pharmaceutical composition
- composition according
- dapanstril
- administered
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862645999P | 2018-03-21 | 2018-03-21 | |
| US62/645,999 | 2018-03-21 | ||
| PCT/US2019/022770 WO2019182981A1 (en) | 2018-03-21 | 2019-03-18 | Methods for treating melanoma |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518374A JP2021518374A (ja) | 2021-08-02 |
| JP2021518374A5 true JP2021518374A5 (https=) | 2022-03-15 |
| JPWO2019182981A5 JPWO2019182981A5 (https=) | 2022-03-15 |
| JP7229565B2 JP7229565B2 (ja) | 2023-02-28 |
Family
ID=67987925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550082A Active JP7229565B2 (ja) | 2018-03-21 | 2019-03-18 | メラノーマを治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11857529B2 (https=) |
| EP (1) | EP3768384B1 (https=) |
| JP (1) | JP7229565B2 (https=) |
| CN (1) | CN111867678B (https=) |
| CA (1) | CA3094307A1 (https=) |
| MX (1) | MX2020009552A (https=) |
| WO (1) | WO2019182981A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12121565B2 (en) * | 2019-09-13 | 2024-10-22 | Duke University | Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies |
| WO2021076444A1 (en) | 2019-10-14 | 2021-04-22 | Olatec Therapeutics Llc | Methods for treating breast cancer |
| JP2024534040A (ja) * | 2021-08-19 | 2024-09-18 | オラテック セラピューティクス， インコーポレイティド | パーキンソン病の治療方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013006708A (es) * | 2010-12-15 | 2013-09-13 | Olatec Ind Llc | Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor. |
| CA2875052C (en) * | 2012-06-05 | 2020-07-14 | Olatec Industries Llc | Method for treating skin inflammatory diseases |
| CN104334165B (zh) * | 2012-06-05 | 2017-09-05 | 欧拉泰克工业有限责任公司 | 用于治疗炎症和疼痛的药物组合物 |
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| US20160362489A1 (en) * | 2015-04-28 | 2016-12-15 | Bristol-Myers Squibb Company | Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody |
| CA3021349A1 (en) * | 2016-04-19 | 2017-10-26 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| WO2018129231A1 (en) * | 2017-01-06 | 2018-07-12 | Olatec Therapeutics Llc | Method for treating multiple sclerosis |
| EP3565540B1 (en) * | 2017-01-06 | 2023-12-06 | Olatec Therapeutics LLC | A pharmaceutical composition for use in treating cardiovascular diseases |
| WO2018204764A1 (en) | 2017-05-05 | 2018-11-08 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| WO2019152627A1 (en) * | 2018-01-31 | 2019-08-08 | Olatec Therapeutics Llc | Method for preventing or treating alzheimer's disease |
-
2019
- 2019-03-18 WO PCT/US2019/022770 patent/WO2019182981A1/en not_active Ceased
- 2019-03-18 JP JP2020550082A patent/JP7229565B2/ja active Active
- 2019-03-18 MX MX2020009552A patent/MX2020009552A/es unknown
- 2019-03-18 EP EP19771591.5A patent/EP3768384B1/en active Active
- 2019-03-18 CA CA3094307A patent/CA3094307A1/en active Pending
- 2019-03-18 CN CN201980020523.3A patent/CN111867678B/zh active Active
-
2020
- 2020-09-15 US US17/021,733 patent/US11857529B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518374A5 (https=) | ||
| FI3788047T3 (fi) | Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi | |
| MY201603A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| JP2017149726A5 (https=) | ||
| JP2008505857A5 (https=) | ||
| JP2005503399A5 (https=) | ||
| RU2018109902A (ru) | Виды комбинированной терапии для лечения рака | |
| MX2023010063A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. | |
| IL273188B (en) | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor | |
| IL292265B2 (en) | Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione) | |
| CN115916778A (zh) | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 | |
| MY204915A (en) | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener | |
| MX2020007971A (es) | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. | |
| JP2021535175A5 (https=) | ||
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| CN111699174A (zh) | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| FI3661510T3 (fi) | Menetelmiä käyttäytymismuutosten hoitamiseksi | |
| AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
| PH12022551110A1 (en) | Methods of treating depressive disorders | |
| RU2008148597A (ru) | Фармацевтические комбинации | |
| CN115666576A (zh) | 一种治疗和/或预防冠状病毒引发的疾病的化合物及其应用 | |
| JP2021505669A5 (https=) | ||
| JPWO2019182981A5 (https=) | ||
| JP2020506169A5 (https=) |